BidaskClub upgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning.
Other equities analysts have also issued research reports about the company. ValuEngine raised Bruker from a hold rating to a buy rating in a research note on Wednesday, August 8th. Morgan Stanley cut their target price on Bruker from $31.00 to $29.00 and set an equal weight rating on the stock in a research note on Friday, July 13th. Zacks Investment Research lowered Bruker from a hold rating to a sell rating in a research note on Tuesday, July 24th. Finally, UBS Group initiated coverage on Bruker in a research note on Tuesday, October 9th. They issued a sell rating and a $30.00 target price on the stock. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $34.63.
NASDAQ:BRKR traded down $1.07 during mid-day trading on Wednesday, hitting $33.83. The company had a trading volume of 736,982 shares, compared to its average volume of 718,089. Bruker has a fifty-two week low of $28.13 and a fifty-two week high of $36.53. The company has a current ratio of 2.22, a quick ratio of 1.27 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $5.40 billion, a price-to-earnings ratio of 27.96, a PEG ratio of 2.11 and a beta of 1.34.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its position in shares of Bruker by 2.6% during the third quarter. Bank of New York Mellon Corp now owns 620,396 shares of the medical research company’s stock worth $20,751,000 after purchasing an additional 15,838 shares during the period. Janus Henderson Group PLC raised its position in shares of Bruker by 4,114.9% during the third quarter. Janus Henderson Group PLC now owns 2,014,706 shares of the medical research company’s stock worth $67,392,000 after purchasing an additional 1,966,906 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in shares of Bruker during the third quarter worth about $205,000. JPMorgan Chase & Co. raised its position in shares of Bruker by 33.4% during the third quarter. JPMorgan Chase & Co. now owns 96,033 shares of the medical research company’s stock worth $3,213,000 after purchasing an additional 24,048 shares during the period. Finally, Stone Ridge Asset Management LLC raised its position in shares of Bruker by 26.0% during the third quarter. Stone Ridge Asset Management LLC now owns 46,984 shares of the medical research company’s stock worth $1,572,000 after purchasing an additional 9,700 shares during the period. 64.86% of the stock is currently owned by institutional investors.
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: Bond
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.